Last week, shares of Hims & Hers Health, Inc. (NYSE: HIMS) fell 8% after the company’s CEO, Andrew Dudum, said he would be eager to hire anti-Israel protesters.
I’m not going to lie. If I were the CEO of a publicly-traded company, I’d delete my Twitter account immediately. It just doesn’t seem worth it. It’s hard enough running a public company. Why would you want to add more stress to your life? Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
But this is more about aggravation than stock valuations. Truth is, no matter what a CEO does or says, if the stock is solid, boycotts and bad press tend to have little effect over the long-haul. Aside from Anheuser-Busch (NYSE: BUD), which is still feeling the pain from a boycott against the company after it hired social media personality Dylan Mulvaney to promote the beer, I’ve never really seen a stock suffer, long-term, anyway, from these types of things.
In fact, after Hims and Hers stock sold off last week, I told some folks to buy it. Those who listened made a quick buck.
This was right before the company announced some fairly impressive earnings last week. Here are some highlights …
- Revenue was $278.2 million for the first quarter of 2024 compared to $190.8 million for the first quarter of 2023, representing an increase of 46% year-over-year.
- Gross margin was 82% for the first quarter of 2024 compared to 80% for the first quarter of 2023.
- Net income was $11.1 million for the first quarter of 2024 compared to a net loss of $(10.1) million for the first quarter of 2023.
The company has plenty of cash, too. And with a nice tailwind that’ll likely push full year revenues up by around 25% for 2024.
Hims and Hers Stock Will Deliver
Say what you want about Andrew Dudum, but the bottom line is that there is very little chance that his recent controversial statements will have any sustaining effect on the long-term value of the company.
As long as the market cooperates, Hims and Hers stock should be trading around $16.50 a share by December. That would be a potential 26% gain. Not bad for what is essentially a boner pill company.
Of course, if you’re looking for more bang for your buck, consider this new stimulus stipends program. Some folks are actually using it to earn nearly $8,000 per quarter.
Now I’m not going to lie: I’m no fan of government stimulus programs. But I’m also not a fan of turning away easy money. If the government is willing to hand over $8,000 per quarter, of course you’re going to take it. Which is why I’m including a link to this report which shows you exactly how you can get some of this action for yourself, and start claiming thousands of dollars in new government stimulus spending.
Indeed, I may be bullislh on boner pills, but I’m far more bullish on getting some of that stimulus money for myself. It’s just easy money. To a new way of life and a new generation of wealth… Jeff Siegel
@JeffSiegel on Twitter
Check us out on YouTube!Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
